Bausch Health to Attend J.P. Morgan Finance Conference
Bausch Health Companies announced that its CFO and other executives will participate in the J.P. Morgan Global Leveraged Finance Conference. Bausch Health owns brands in eye care and medical aesthetics. Its presence at a major financial conference can signal potential capital-raising, M&A, or other strategic financial activities relevant to its brand portfolio.
- The J.P. Morgan Global Leveraged Finance Conference is a key event for companies with significant debt to communicate with investors and explore financing options. Bausch Health carries a total debt of approximately $21.5 billion. - The company is actively working to reduce its debt, having recently announced a $900 million debt reduction and completed a $7.9 billion refinancing to extend its debt maturities. - Bausch Health's medical aesthetics division, Solta Medical, is a significant growth driver, with revenues increasing by 25% in the third quarter of 2025. Solta's brands include Thermage, Fraxel, Clear + Brilliant, and VASER. - The Thermage brand recently surpassed 5 million treatments, indicating strong consumer demand in the non-invasive skin tightening market. - Bausch Health previously planned an IPO for Solta Medical in 2022 to help pay down debt but suspended it due to market conditions, opting to retain the cash-flow-positive business for now. - The company has a history of transformation, rebranding from Valeant Pharmaceuticals in 2018 after a period of controversy related to its business practices and debt-fueled acquisitions. - Bausch Health also owns Ortho Dermatologics, a major prescription dermatology company, and holds a majority stake in the publicly traded eye-health company Bausch + Lomb. - The company's stock has experienced significant volatility, including a sharp drop in July 2024 following unconfirmed reports of a potential bankruptcy filing to manage its debt, highlighting investor sensitivity to its financial health.
